Filter News

Myovant Strengthens Management Team and Adds New Directors to the Board

Published: Nov 07, 2018

BASEL, Switzerland, Nov. 7, 2018 /PRNewswire/ -- Myovant Sciences, Ltd. (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich, formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold, formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development. In addition, Myovant has appointed industry veterans Myrtle Potter, Mark Guinan, and Frank Torti, M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.

"With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth," said Lynn Seely, M.D., President and CEO of Myovant. "Ms. Potter's decades of commercial experience perfectly position her to chair Myovant's Board of diverse industry and healthcare leaders. Together, we are committed to achieving our mission of becoming the leading company in women's health and endocrine diseases."

Additions to Myovant's Management Team

Ms. Sablich previously served as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair®, Breo, Anoro®, Incruse®, Tanzeum™, Levitra®, and Trelegy. Prior to that, she was Vice President, Global Medicines Commercialization in the United Kingdom, and before that, Vice President, Vaccines Commercial Strategies. Before joining GSK, Ms. Sablich spent 15 years at Merck, where she held positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas. Ms. Sablich has extensive experience in direct-to-consumer marketing, having led the development of consumer strategies and national multi-channel campaigns for multiple products. She is currently a member of the Board of Directors of AllerGenis LLC. She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania.

Mr. Nornhold previously served as Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), where he was responsible for Impax's manufacturing, supply chain, quality and technical operations. Prior to that, he served as Impax's Senior Vice President, Global Quality Affairs, and was responsible for establishing a sustainable quality and compliance program. Prior to Impax, Mr. Nornhold served as Vice President, Quality Operations – International for Watson Pharmaceuticals, Inc. (now Allergan PLC), and was responsible for ex-U.S. manufacturing sites for both dosage and active pharmaceutical ingredients. While at Watson, he also served as Vice President, U.S. Quality Operations, where he led the development and execution of quality initiatives for all U.S. sites. Earlier in his career, he held numerous leadership positions in the pharmaceutical industry. Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.

New Myovant Directors

Ms. Potter currently serves as Vant Operating Chair for Roivant Pharma, a division of Roivant Sciences. She previously served as Chief Executive Officer of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech. Prior to Genentech, she held various positions, including President of Cardiovascular/Metabolics at Bristol-Myers Squibb. She is a graduate of the University of Chicago. In addition to serving on our Board, Ms. Potter also serves on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma. Ms. Potter has previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc.

Mr. Guinan serves as the Executive Vice President and Chief Financial Officer for Quest Diagnostics Inc. He previously served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the healthcare industry. Prior to that, he served in a number of finance and operations roles in a long career at Johnson & Johnson, including as Vice President, Chief Procurement Officer, and as CFO of the pharmaceutical business. Before joining Johnson & Johnson, Mr. Guinan held a number of financial roles at Procter & Gamble. He received a B.A. in economics from the University of Notre Dame and an M.B.A. from Olin Business School at Washington University in St. Louis.

Dr. Torti serves as Vant Investment Chair for Roivant Pharma, a division of Roivant Sciences. Prior to Roivant, he was a partner at New Enterprise Associates (NEA), a leading venture capital firm. At NEA, Dr. Torti managed early and growth-stage investments in numerous healthcare companies developing and commercializing new drugs and medical devices. Prior to NEA, Dr. Torti was a researcher at the Duke University Center for Clinical & Genetic Economics where he was involved in clinical trial research and economic evaluations of multinational clinical trials. In addition to serving on our Board, Dr. Torti also serves on the boards of several other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences, Dermavant Sciences and Respivant Sciences. Dr. Torti received an M.D. from the University of North Carolina School of Medicine and an M.B.A. with distinction from Harvard Business School.

Myovant's other directors include Kathleen Sebelius, former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy, the founder and CEO of Roivant Sciences; Terrie Curran, President, Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely, M.D., President and Chief Executive Officer of Myovant.

About Myovant Sciences

Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases. Myovant's lead product candidate is relugolix, an oral, once-daily small molecule that acts as a GnRH receptor antagonist. Myovant has initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 and 2), two in women with pain associated with endometriosis (SPIRIT 1 and 2), and one in men with advanced prostate cancer (HERO). Myovant is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that is in Phase 2a development for the treatment of female infertility as part of assisted reproduction. Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide. Over time, Myovant intends to expand its development pipeline to include other potential treatments for women's health and endocrine diseases. For more information, please visit Myovant's website at www.myovant.com.

Forward-Looking Statements

This press release contains forward-looking statements, including without limitation: Myovant's focus on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases; and the statements and quote related to the timing of reporting clinical trial results. Forward-looking statements can be identified by the words "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "likely," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "to be," "will," "would," or the negative or plural of these words or other similar expressions or variations, although not all forward-looking statements contain these identifying words. Myovant cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors known and unknown that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled "Risk Factors" set forth in Myovant's Quarterly Report on Form 10-Q which was filed with the Securities and Exchange Commission on August 7, 2018, and other filings that Myovant makes with the SEC from time to time. These risks are not exhaustive. New risk factors emerge from time to time and it is not possible for its management to predict all risk factors, nor can Myovant assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Except as required by law, Myovant undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.